Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hopefully, it's hard to determine a due date if any...
BIGG setting up nicely...
Sharky the FB icon above refers to a bio company and not to bigg tree. Maybe would it be good to modify the link accordingly thanks !!
I think we are good
tose two trades at .0076 were providential for the buyers
Is this deadline still valid?
Good morning
"In 2015, we will also consider methods of increasing shareholder value," said Mr. Xiaobin Liu, the CEO of the company. "We have generated substantial free cash flow and made accretive acquisitions. We have also bought back some stock. However, we recognize our stock is highly undervalued. We ended 2014 with net cash pe r share of $3.77*, more than twice the current stock price. Our shareholders equity was $312.1 million ($8.02 per share)*. During 2015, we will consider a number of possible ways of increasing shareholder value including stock buybacks, roadshows, the possibility of dual listing on other exchanges, and etc. We value our shareholders and want to take steps that will benefit them."
We incurred a total of $488,880 in exploration costs during 2014. On January 30, 2015 we announced that we had found natural gas resources under our bromine well in the Sichuan area. The company will hire a third party to conduct a survey of the geological structure and complexity analysis and the economics of the natural gas under this well. The Company is in the final stage of discussion with the expert company to finalize the service agreement. The company intends to invest approximately $10 million for further development in 2015, if the project is commercially viable.
Agreed but I think the only obligation for Chinese compagnies is to file the annual report. Let us hope it turns out well
I like their accounts being thoroughly audited . Good sign for me on the contrary
Agreed , shares are trading very low at about their cash per share val ue
0.0082x0.0091
ANSWER FROM CDII:
From: "Peisha Shen" <Peisha.Shen@cdii.net> to: xxxx>Cc: "Ryan Lu" <Ryan.Lu@cdii.net>
Good Morning,
Thank you for your concern in BIGG. The annual report has been delay due to accounting issues between the company and the auditors, we are currently working closely with both parties to try to resolve the issue and file the reports. We hope you will continue to support BIGG. Thank you!
Regards,
Peisha Shen
---------------------------------------------------------------------------
Operation Manager
CD International Enterprises, Inc. (OTC: CDII)
431 Fairway Drive, Suite 200
Deerfield Beach, FL 33441
Office: 954.363.7333 ext. 325
Fax: 954.363.7320
Skype id: peisha_cdii
Email: peisha.shen@cdii.net
Website: www.cdii.net
Follow CDII on:
----------------------------------------------------------------------------------
The information contained in this e-mail message and its attachments is intended solely for the use of the individual(s) to whom it is addressed and may contain information that is legally privileged and confidential or otherwise exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this e-mail is strictly prohibited. If you have received this communication in error, please immediately notify me and destroy the original message. Thank you.
at 7.30 AM indeed. That will be interesting, but the most exciting part will be in three months with Q1 release reflecting acquisition of chemical company... Hold
Just the beginning imho
I already own 0.1 % of the company o-)
True, when news hits, this might go parabolic. There is No dilution, which is very rare. Patience has been and is the keyword
FYI:
Big Tree is mentioned in the annual report of CD INTERNATIONAL ENTERPRISES, INC. AND SUBSIDIARIES: (look at form
http://www.sec.gov/Archives/edgar/data/1088787/000144878815000003/cdii10-k.htm
At September 30, 2013, we have $116,550 receivable due from 15,750,000 shares of common stock of China Logistics Group, Inc (OTC: CHLO), and $48,750 due from 37,500,000 shares of common stock of Dragon Capital Group, Corp. (Pink Sheet: DRGV). At September 30, 2012, we have $7,653,656 receivable due from 2,542,743 shares of common stock of Big Tree Group, Inc (OTC: BIGG).
Hello. I have just sent an email to the lady. I will keep you posted should I receive any answer.
Based on the fundamentals of this company and the submission of a report showing 30-40 millions of revenues , I believe confidence will be restored and pps could attain .05 quite rapidly. I took a starter position yesterday of 200k shares and am ready to accumulate should it go down further. Actually I am relaxed and confident. I have been following this for a year now and nothing has really changed except Asher ´s escape which is very good. Price Target IMHO is 20 if management COMMUNICATES, but this seems to be something missing in China. Keep faith...
Thanks for your DD , Bigg is bound to rise soon Imho. Just a question of patience. Largely oversold and way undervalued ...they sell products and earn money.
Wait it can go to ten shortly ...
NEWS: http://www.prnewswire.com/news-releases/can-fite-submitted-phase-ii-study-protocol-with-cf102-to-treat-patients-with-advanced-liver-cancer-243932411.html
PETACH TIKVA, Israel, Feb. 6, 2014 /PRNewswire/ -- Can-Fite BioPharma (TASE: CFBI), (OTC: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 drug candidate has been submitted.
The company plans to conduct the Phase II study in Israel, Europe and the US and will include 78 subjects (less than what has been reported previously since the company is treating a patient population with a more advanced disease) with second-line treatment of advanced hepatocellular carcinoma with Child-Pugh Class B cirrhosis. The study will investigate the efficacy and safety of CF102 vs. placebo. The protocol has been submitted to the ethics committee in Israel and the company intends to follow up with European and US submissions shortly. The study protocol was developed with the assistance of Dr. Keith Stuart, MD, Chairman, Department of Hematology and Oncology Professor of Medicine, Tufts University School of Medicine a well-known internationally expert in Liver Cancer.
The US Food and Drug Administration (FDA) has granted Orphan Drug designation for CF102, for the treatment of hepatocellular carcinoma.
According to Global Industry Analysts, the global liver cancer drug market is expected to exceed $2 billion by 2015.
The company reported earlier that data from the Phase I/II study was published recently in The Oncologist, one of the leading journals in this field, and was presented at the 18th World Congress on Advances in Oncology. The company reported that the Phase 1/II study data demonstrated that the trial objectives were successfully achieved, demonstrating a very favorable safety profile for CF102 in a patient population with hepatocellular carcinoma and Child-Pugh cirrhosis classes A and B. In addition, the median overall survival time was very encouraging given that most patients were treated in the second-line setting and some were Child-Pugh Class B. Another finding indicated that the A3 adenosine receptor, which is the target of CF102, can serve as a biomarker to predict the patients' reaction to treatment with CF102. Interestingly, one of the patients included in the Phase 1/II study has been treated for 4 years with CF102 and is continuing to be treated, with CF102.
About CF102
CF102 is a small orally bioavailable drug which binds with high affinity and selectivity to the A3 adenosine receptor. The latter is highly expressed in tumor cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug. In our pre-clinical and clinical studies, CF102 induces a robust anti-tumor effect via de-regulation of the Wnt signaling pathway, resulting in apoptosis of liver cancer cells.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (the "TASE") (TASE: CFBI). Level II American Depository Receipts of the Company currently trade on the NYSE MKT (NYSE MKT: CANF). Can-Fite, which commenced business activity in 2000, was founded by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys in Israel. Dr. Fishman serves as the Chief Executive Officer of Can-Fite. Dr. Fishman founded Can-Fite on the basis of her scientific findings, and Can-Fite is focused on the development of small molecule orally bioavailable drugs, in particular, ligands that bind to the A3 adenosine receptor. Such drugs mediate anti-inflammatory and anti-cancer effects and the A3AR is developed as a biological predictive marker. Can-Fite's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis. Can-Fite's CF102 drug candidate is being developed for the treatment of liver diseases and CF602 is being developed for the treatment of inflammation and sexual dysfunction. To date, more than 1000 patients have participated in clinical trials conducted by Can-Fite. Can-Fite previously spun off it's activity in the ophthalmic field to OphthaliX Inc., in which it holds 82%, and is currently listed on the U.S. Over-the-Counter Markets (OTCQB: OPLI).
Contact:
IRTH Communications, LLC
Robert Haag
canfy@irthcommunications.com
Forward-Looking Statements
This press release contains forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission (the "SEC"), press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Can-Fite BioPharma
RELATED LINKS
http://www.canfite.com/
My News
?Release contains wide tables.
View fullscreen.
Journalists and Bloggers
The first priorities are to restructure the Company’s balance sheet and to improve overall cash flow management. The opportunity to replace tobacco cigarettes is not only a great business endeavor, but also represents an excellent opportunity to do something positive for society. ECIG is the best positioned company globally to take on this challenge, and with a strengthened and restructured balance sheet, coupled with a portfolio of strong brands, the potential of ECIG is tremendous. My goal will be to drive controlled, profitable growth globally and to deliver superior and sustainable returns to our shareholders. I look forward to working with our CEO Brent Willis to deliver on these commitments
NEWSwww.thestarphoenix.com/business/Ceres+starts+operations+Northgate+logistics/10723998/story.html
Big Tree Group, Inc. (BIGG) Executes Formula of Success in Global Toy Market 9/26/14
http://blog.qualitystocks.net/category/big-tree-group-inc-bigg/
Tablets and smartphones are strong contenders when it comes to competing for a child’s attention, but trends out of the world’s Top toy producing market, China, show that toys and games are standing their ground. There’s also tight competition between competing toy producers –what it takes for a win in this race is incredible inventory, an extensive buyers network and innovation.
China produces roughly 75% of toys worldwide, creating immense pressure on competing toy producers. Market research company Euromonitor estimates that total retail sales of toys and games in China have soared to Rmb68.9 billion in 2013 from Rmb46.3 billion in 2010, representing an average annual growth rate of 14.2%. Among China’s main toy production and export bases is Guangdong, which has manufacturing activities centered around Shenzhen, Dongguan, Guangzhou, Shantou’s Chenghai and Foshan.
Shantou City is known as the “Toy Capital” of the world, and it’s here that Big Tree Group, Inc. conducts operations through its two fully operating subsidiaries, Big Tree Brunei and Big Tree Shantou. Big Tree operates a testing facility to ensure product integrity of the toys that it puts out for display in its 21,000-square-foot showroom.
The company has become a “one-stop-shop” for the international sourcing and distribution of toys and other related products, securing its foothold in the global toy industry and establishing itself as an authorized sales agent for more than 8,000 toy manufacturers. Big Tree’s inventory includes more than 300,000 varieties of toy products such as remote control toys, digital toys, sports toys, play sets, educational toys, dolls and infant toys. The company has built a strong reputation for its inventory, and thousands of international toy purchasers from around the world browse the Big Tree facility to find the next times to hit main street shelves.
In 2011, Big Tree flexed its innovative side and began selling its own patented construction toy, the Magic Puzzle (3D). For the time being, the proprietary Big Tree Magic Puzzle is promoted and distributed solely in the Chinese domestic market, available through Big Tree Shantou’s online store as well as in several retail locations. In response to positive consumer and retail feedback, Big Tree is also evaluating global marketing and distribution of the Magic Puzzle.
Under the leadership of an innovative management team that understands what it takes to succeed a competitive and evolving market, Big Tree operates an aggressive growth strategy to remain a competitive player in the world’s toy industry.
For more information visit www.bigtreegroup.net
Let us hear your thoughts: Big Tree Group, Inc. Message Board
arounf November as last one was in August http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10153938
i think 700k is only the first payment of a royalty settlement plan we hâve nô détails
www.goldmanresearch.com/20131105628/Opportunity-Research/ip-firm-could-ultimately-be-worth-hundreds-of-millions.html
online.wsj.com/article/PR-CO-20131105-907399.html
ENIP Goldman report: from October 2013 but 3$ target...
www.goldmanresearch.com/Download.../342-ENIP-10.16.13-1.html
As you say, I do not understand it either,maybe a mistake, anyway good luck guys
I live abroad in Europe. My broker is not US...And no I do not know how it happened frankly. I have nothing to win either as I do not own shares anymore
Hey guys, just to let you know, my account shows I received the divvy two days ago in the form of 50 shares. I was surprised because I sold my 5 million TLNUF two weeks ago. So 50/5000000= 1 for 100000 shares owned. I guess it's the way the divvy has been distributed. I will not post the screen of my account here but what I say is true. These 50 shares are probably restricted because I cannot sell them now.
Cheers
Thanks a lot Doc!
Thank you Farmer
Good morning Doc
where did you learn about charts? Investopedia? Do you have some good sources? I wish to get trained on that, thks!
www.murphyanalytics.com/uploads/TLNUF_Initiation.pdf
Interesting to see that this report talks about a possible $0.27 in the coming quarters with 81000000 O/S shares. If we now count 3 billion o/s shares, it's still around a fully diluted value of $0.007, not bad
With a negative cash balance as of 6/30/13, a working capital deficit of ($40,000), and no reported revenues, TLNUF is dependent entirely on new capital to continue operations. The Company is seeking to raise $2.5 million in capital to fund development, capital expenditures, acquisitions, sales & marketing, and general & administrative expenses. If the Company is able to raise sufficient capital to continue operations, there is a significant market opportunity that remains in Telecorp’s target markets, especially among small to medium sized businesses (SMB). Announced 9/30/13, Telecorp’s agreement with the Retail Merchants’ Association of Canada (RMA) targets this SMB market opportunity and is consistent with the Company’s identified sales strategies. The Company1has made its business plan, investor presentations, and financial projections available at OTCMarkets.com. While a loss is projected for 2014, the Company is targeting $2.7 million in net income in 2015 growing to $21.8 million by 2018. For illustration purposes only, if it is assumed the Company issues shares to fund a $2.5 million capital raise, the implied outstanding shares may increase to 105 million, implying EPS of $0.034 / share in 2015 and $0.59 / share in 2018 if the Company hits its revenue, margin, and expense projections. With relevant market benchmarks trading at 16x – 21x P/E, the implied price potential for TLNUF may be $0.60 share in 2015. Discounted at 50% for 2 years, the implied price potential is $0.27 over the coming quarters if Telecorp is able to begin to demonstrate the ability to raise capital and execute its business plan. While the possible range of prices for every stock is a theoretically unlimited upside to a downside of $0, and although the Company faces significant financial and operational challenges, there is an attractive and growing opportunity in Telecorp’s target markets.
don't think they have filed yet